Gene Therapy Shows Promise in Treating Craniosynostosis in Infants

Researchers at the University of Iowa are developing a gene therapy that could potentially eliminate the need for invasive skull surgery in babies with craniosynostosis, a condition where the skull bones fuse too early. The researchers have identified a key gene, miR-200a, which when injected, halted the development of craniosynostosis in infant mice that were genetically programmed to develop it. While there are still several steps to take before human trials can begin, including obtaining FDA approval and producing medical-grade DNA, the team is optimistic about the potential of this new treatment. According to the National Center for Biotechnology Information, approximately 1 in 2,000 babies is born with craniosynostosis, a condition that can cause abnormal head shape and potentially impair brain growth if left untreated.

Key Takeaways:

• Researchers at the University of Iowa have developed a gene therapy that has shown promise in treating craniosynostosis in infants.
• The gene therapy targets a key gene, miR-200a, which was found to be responsible for the development of craniosynostosis in mice.
• The researchers plan to submit their study to the FDA for approval and hope to begin human trials in the next 1-2 years.
• The gene therapy is a simple injection below the scalp, which is a significant improvement over the current lengthy surgery process.
• Craniosynostosis is a rare condition that affects approximately 1 in 2,000 babies, and if left untreated, can cause abnormal head shape and potentially impair brain growth.
• The researchers have partnered with a nonprofit organization, CAPPSKids, which supports families of children with craniosynostosis and related craniofacial issues.
• Early detection of the condition is extremely limited, but new potential options like gene therapy could help improve outcomes for affected babies.
• Laura Kacmarynski, a UI Department of Otolaryngology associate professor, believes that advancements in treatment options like gene therapy could drive improvements in diagnostic training.

Statistics:

• Approximately 1 in 2,000 babies is born with craniosynostosis.
• Craniosynostosis affects approximately 1 in 2,500 births.
• 95% of babies with craniosynostosis require surgery to correct the condition.
• The current lengthy surgery process for craniosynostosis involves cranial vault remodeling.
• The gene therapy developed by the researchers involves a simple injection below the scalp.
• The FDA approval process for human trials will take 1-2 years.
• The gene delivery packet developed by the researchers is 95 nanometers in size.

Sources:

• National Center for Biotechnology Information
• University of Iowa Department of Anatomy and Cell Biology
• University of Iowa Department of Otolaryngology
• CAPPSKids
• U.S. Food and Drug Administration (FDA)